SPY303.53+4.45 1.49%
DIA255.77+5.52 2.21%
IXIC9,412.36+72.14 0.77%

RBC Capital Maintains Outperform on Flexion Therapeutics, Lowers Price Target to $18

RBC Capital maintains Flexion Therapeutics (NASDAQ:FLXN) with a Outperform and lowers the price target from $20 to $18.

Benzinga · 05/08/2020 13:13

RBC Capital maintains Flexion Therapeutics (NASDAQ:FLXN) with a Outperform and lowers the price target from $20 to $18.